A randomized, double-blind, placebo-controlled, phase III study evaluating the efficacy and safety of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab as first line therapy for locally advanced or metastatic non-squamous and squamous non-small cell lung cancer subjects (CANOPY-1)
This research study, called CANOPY-1, is for people with advanced non-small cell lung cancer. It aims to see if adding one or two new drugs (pembrolizumab and canakinumab) to standard chemotherapy is better than chemotherapy alone. Pembrolizumab works with your immune system, while canakinumab targets inflammation. The study will carefully check how safe these drug combinations are and how well they work at shrinking tumours and helping people live longer. It’s a ‘Phase III’ study, meaning it’s a big, important step before these treatments could be widely used. All participants will be closely monitored by a healthcare team to ensure their wellbeing.
At a glance
What is this study about?
This research study, known as CANOPY-1, is looking into new ways to treat non-small cell lung cancer that has spread or is advanced. We already know that chemotherapy is a common treatment for this type of cancer. This study wants to see if adding specific new medications to chemotherapy can make the treatment even better.
The main idea is to combine standard chemotherapy with a drug called pembrolizumab. Pembrolizumab helps your body's own immune system fight the cancer. On top of this, some people in the study might also receive an additional drug called canakinumab, which works by reducing inflammation in the body. The researchers believe that these combinations might be more effective at stopping the cancer from growing and could potentially help people live longer.
Because this is a 'Phase III' study, it means it's a large and important step. It's designed to confirm whether these new drug combinations are both safe enough and work better than existing treatments before they could be approved for general use. The study will very carefully monitor patients' health, looking for any side effects and checking how well the treatments are working, for example, by seeing if tumours shrink.
Key takeaways
- This study evaluates new drug combinations for advanced non-small cell lung cancer.
- It combines standard chemotherapy with immunotherapy (pembrolizumab), with or without an anti-inflammatory drug (canakinumab).
- The main goals are to check treatment safety, how well it shrinks tumours, and if it helps people live longer.
- It's a large, important 'Phase III' study, a key step for new treatments.
- Participation involves regular clinic visits, tests, and careful monitoring.
- You can stop participating at any time.
Who may be eligible?
To join this study, participants must be at least 18 years old. Both men and women are welcome to take part. The study is specifically for individuals who have been diagnosed with non-small cell lung cancer that is locally advanced (meaning it has grown into nearby tissues) or has spread to other parts of the body (metastatic).
There will be other detailed medical checks to make sure the treatment is suitable and safe for each person. These will confirm your general health, specific cancer type, and any other medical conditions you might have. Your doctor and the study team will discuss all of these requirements with you to see if you can take part.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you at least 18 years old?
- Have you been diagnosed with non-small cell lung cancer that is locally advanced or has spread?
- Are you able to attend regular hospital visits and appointments?
- Are you willing to undergo necessary tests like blood samples and scans?
- Are you starting your first main treatment for advanced lung cancer?
What does participation involve?
If you join this study, you will have regular visits to the clinic for medical check-ups, blood tests, and scans to monitor your health and how the treatment is working. You will receive the study medications (chemotherapy, pembrolizumab, and possibly canakinumab or a placebo) according to a specific schedule, which will be explained in detail. You will be closely monitored for any side effects, and the team will ask you about your symptoms and how you are feeling. The exact number of visits, tests, and total duration will vary, but the study team will provide you with a clear schedule. You may also need to complete questionnaires about your quality of life.
Potential risks and benefits
Locations (2)
- —UnverifiedSpain
- —UnverifiedGermany
Common questions
What is non-small cell lung cancer?
It's the most common type of lung cancer, and this study focuses on advanced cases where it has spread or is difficult to treat locally.
What does 'first line therapy' mean?
It means the treatment being tested would be the first main treatment you receive for your advanced lung cancer, rather than a treatment used later if others haven't worked.
What is a 'placebo'?
A placebo is a dummy treatment that looks like the real drug but contains no active medicine. It helps researchers fairly compare how well the actual drugs work.
What does a 'Phase III' study mean?
It's a large final stage of testing for a new treatment. It confirms if a drug is safe and effective compared to existing treatments before it can be used more widely.
Will I know which treatment I'm getting?
No, this is a 'double-blind' study, meaning neither you nor your study doctor will know whether you are receiving canakinumab or the placebo. This helps ensure the results are fair.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.